Cargando…

Microbial Metabolites in Cystic Fibrosis: A Target for Future Therapy?

Detalles Bibliográficos
Autores principales:	Widder, Stefanie, Knapp, Sylvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2019
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670038/ https://www.ncbi.nlm.nih.gov/pubmed/30965015 http://dx.doi.org/10.1165/rcmb.2019-0081ED

Ejemplares similares

The Future of Highly Effective Modulator Therapy in Cystic Fibrosis
por: Daines, Cori L., et al.
Publicado: (2021)

Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy
por: Martin, Christian, et al.
Publicado: (2023)

Future therapies for cystic fibrosis
por: Allen, Lucy, et al.
Publicado: (2023)

Steps toward Cell Therapy for Cystic Fibrosis
por: Koh, Kyung Duk, et al.
Publicado: (2020)

Ecological networking of cystic fibrosis lung infections
por: Quinn, Robert A, et al.
Publicado: (2016)

Indole microbial metabolites: expanding and translating target(s)
por: Mani, Sridhar
Publicado: (2017)

Cystic fibrosis revisited
por: Kulkarni, H, et al.
Publicado: (2019)

Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model
por: Lu, Shiping, et al.
Publicado: (2021)

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in the Cystic Fibrosis Registry
por: Thompson, Cassandra, et al.
Publicado: (2023)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

The Need for Precision Therapies as Determined by Genetic Signature for Cystic Fibrosis
por: Zahir, Farah R.
Publicado: (2021)

The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
por: Maetz, Jessica, et al.
Publicado: (2021)

Cystic fibrosis: current therapeutic targets and future approaches
por: Rafeeq, Misbahuddin M., et al.
Publicado: (2017)

Clinical Advances in Cystic Fibrosis
por: Imperlini, Esther, et al.
Publicado: (2022)

Cystic Fibrosis: “Ionocyte Modulators”?
por: Shah, Viral S., et al.
Publicado: (2023)

Cystic Fibrosis Lung Disease and Immunometabolism. Targeting the NLRP3 Inflammasome
por: Cantin, André M.
Publicado: (2019)

A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants
por: Wainwright, Claire E.
Publicado: (2022)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Identification of Exhaled Metabolites in Children with Cystic Fibrosis
por: Weber, Ronja, et al.
Publicado: (2022)

Cystic fibrosis in Brazil: achievements in survival
por: Vendrusculo, Fernanda Maria, et al.
Publicado: (2021)

The Impact of COVID-19 in Cystic Fibrosis
por: Flume, Patrick A., et al.
Publicado: (2022)

The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
por: Lommatzsch, Sherstin T., et al.
Publicado: (2019)

Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
por: Hoppe, Jordana E., et al.
Publicado: (2022)

Gene Therapy for Cystic Fibrosis: Recent Advances and Future Prospects
por: Lomunova, M. A., et al.
Publicado: (2023)

The cystic fibrosis lower airways microbial metagenome
por: Moran Losada, Patricia, et al.
Publicado: (2016)

Cystic Fibrosis Inflammation: Hyperinflammatory, Hypoinflammatory, or Both?
por: Murphy, Sean V., et al.
Publicado: (2019)

Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Comparing cystic fibrosis outcomes across the pond
por: Taylor-Robinson, David C, et al.
Publicado: (2015)

Cystic fibrosis-related diabetes: The unmet need
por: Pozo, Leonardo, et al.
Publicado: (2020)

Preclinical Modeling for Therapeutic Development in Cystic Fibrosis
por: Bonfield, Tracey L.
Publicado: (2020)

Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021)

How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
por: Ben-Meir, Elad, et al.
Publicado: (2022)

Is PI3K a Villain in Cystic Fibrosis?
por: Natarajan, Viswanathan
Publicado: (2020)

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
por: Pallenberg, Sophia T., et al.
Publicado: (2022)

A new future for patients with cystic fibrosis
por: Pullen, Lara C.
Publicado: (2020)

Targeted therapies to improve CFTR function in cystic fibrosis
por: Brodlie, Malcolm, et al.
Publicado: (2015)

Shifting Landscape of Airway Infection in Early Cystic Fibrosis
por: Hoppe, Jordana E., et al.
Publicado: (2019)

Nutrition in Cystic Fibrosis: as important as the management of pulmonary disease
por: Adde, Fabíola Villac
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_11o65re216gndiac8omi7b0022